3/19 TML-1209811
ONCOGENIC
DRIVERS
ARE
CONSIDERED
PREDICTIVE
BIOMARKERS IN NSCLC
BRAF V600
IS AN ACTIONABLE TARGET IN METASTATIC NSCLC
THE
FIRST AND ONLY FDA-APPROVED targeted combination therapy for patients with metastatic NSCLC with BRAF V600 mutation
